Reuters logo
10 months ago
BRIEF-Kempharm receives clearance from FDA to initiate clinical program for KP415
October 11, 2016 / 12:11 PM / 10 months ago

BRIEF-Kempharm receives clearance from FDA to initiate clinical program for KP415

1 Min Read

Oct 11 (Reuters) - Kempharm Inc :

* Kempharm receives clearance from FDA to initiate clinical program for KP415, an investigational prodrug of D-threo-methylphenidate for the treatment of ADHD

* Kempharm Inc says expects to commence and complete proof of concept human trials prior to end of 2016

* Kempharm Inc says kempharm anticipates submitting a new drug application (NDA) submission for kp415 as early as 2018

* Kempharm Inc - additional human clinical trials initiating during first half of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below